Exact Sciences Corporation $EXAS Holdings Cut by Vanguard Group Inc.

Vanguard Group Inc. lowered its stake in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 0.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,808,477 shares of the medical research company’s stock after selling 98,982 shares during the period. Vanguard Group Inc. owned about 9.41% of Exact Sciences worth $974,302,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of EXAS. Great Lakes Advisors LLC raised its holdings in shares of Exact Sciences by 3.7% during the first quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock worth $215,000 after acquiring an additional 178 shares in the last quarter. Capital Asset Advisory Services LLC increased its position in Exact Sciences by 4.8% in the 3rd quarter. Capital Asset Advisory Services LLC now owns 3,941 shares of the medical research company’s stock worth $216,000 after purchasing an additional 182 shares during the last quarter. DekaBank Deutsche Girozentrale raised its stake in shares of Exact Sciences by 0.4% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 58,333 shares of the medical research company’s stock worth $3,127,000 after purchasing an additional 217 shares in the last quarter. Assetmark Inc. raised its stake in shares of Exact Sciences by 7.2% during the 3rd quarter. Assetmark Inc. now owns 3,588 shares of the medical research company’s stock worth $196,000 after purchasing an additional 242 shares in the last quarter. Finally, Westside Investment Management Inc. lifted its holdings in shares of Exact Sciences by 100.0% during the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock valued at $31,000 after buying an additional 271 shares during the last quarter. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on EXAS. Robert W. Baird set a $105.00 price objective on shares of Exact Sciences in a research report on Thursday, November 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Exact Sciences in a research note on Thursday, January 22nd. Benchmark downgraded shares of Exact Sciences from a “buy” rating to a “hold” rating in a report on Monday, November 24th. Jefferies Financial Group cut shares of Exact Sciences from a “buy” rating to a “hold” rating and upped their price objective for the stock from $90.00 to $105.00 in a report on Monday, November 24th. Finally, Wolfe Research downgraded shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. One research analyst has rated the stock with a Buy rating, twenty-one have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $91.00.

Exact Sciences Price Performance

NASDAQ EXAS opened at $103.43 on Friday. Exact Sciences Corporation has a 1 year low of $38.81 and a 1 year high of $103.54. The company has a fifty day simple moving average of $102.31 and a 200 day simple moving average of $77.72. The company has a current ratio of 2.43, a quick ratio of 2.44 and a debt-to-equity ratio of 0.97. The company has a market cap of $19.74 billion, a P/E ratio of -94.03, a P/E/G ratio of 2.35 and a beta of 1.42.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.During the same quarter last year, the business posted ($0.06) EPS. The business’s revenue was up 23.1% compared to the same quarter last year. On average, sell-side analysts predict that Exact Sciences Corporation will post -0.58 EPS for the current year.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.